{"id":3617,"date":"2020-10-19T14:35:19","date_gmt":"2020-10-19T18:35:19","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/"},"modified":"2026-07-15T15:57:43","modified_gmt":"2026-07-15T19:57:43","slug":"4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/19\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/","title":{"rendered":"4\u00e8me Congr\u00e8s Annuel Gene Therapy for Rare Disorders Europe \u2013 Format virtuel"},"content":{"rendered":"\n<strong>Gensight Biologics<\/strong> participera \u00e0 la 4\u00e8me \u00e9dition du congr\u00e8s annuel <a href=\"https:\/\/genetherapy-europe.com\/\" target=\"_blank\" rel=\"noopener\"><strong>Gene Therapy for Rare Disorders Europe<\/strong><\/a> qui se tiendra dans un format virtuel du lundi 26 octobre au mercredi 28 octobre 2020.\n\n<strong>Magali Taiel, <\/strong>Directeur M\u00e9dical, donnera une pr\u00e9sentation orale et participera \u00e0 un panel de discussion.\n\n&nbsp;\n\n<strong><span style=\"color: #33bdbc\">Pr\u00e9sentation orale<\/span>\u2013 Titre :<\/strong> <strong>Outlining Key Regulatory Pathway Differences in the US &amp; Europe \u2013 Learnings from development of Lumevoq Gene Therapy in LHON subjects<\/strong>\n<ul>\n \t<li>Comparing and contrasting EMA &amp; FDA regulatory pathways<\/li>\n \t<li>Working effectively with regulators to meet their requirements<\/li>\n \t<li>Outlining the advantages of more common guidances between different regulatory agencies<\/li>\n<\/ul>\n<strong>Date <\/strong>: mardi 27 octobre 2020\n\n<strong>Heure <\/strong>: 11:30am \u2013 12:00pm GMT (12h30 \u2013 13h heure locale de Paris)\n\n<strong>Session<\/strong>:\u00a0 CLINICAL &#8211; Exploring the European Regulatory Landscape\n\n&nbsp;\n\n<strong><span style=\"color: #33bdbc\">Panel Discussion<\/span> \u2013 Titre :<\/strong> <strong>Exploring the Industry Response to COVID-19 &amp; Identifying Key Learnings<\/strong>\n\n<strong>Date <\/strong>: mardi 27 octobre 2020\n\n<strong>Heure <\/strong>: 4:45am \u2013 5:15pm GMT (17h45 \u2013 18h15 heure locale de Paris)\n\n<strong>Session <\/strong>: SHARING UPDATES ON THE FUTURE GENE THERAPY LANDSCAPE\n\n&nbsp;\n","protected":false},"excerpt":{"rendered":"<p>Gensight Biologics participera \u00e0 la 4\u00e8me \u00e9dition du congr\u00e8s annuel Gene Therapy for Rare Disorders Europe qui se tiendra dans un format virtuel du lundi 26 octobre au mercredi 28 octobre 2020. Magali Taiel, Directeur M\u00e9dical, donnera une pr\u00e9sentation orale et participera \u00e0 un panel de discussion. &nbsp; Pr\u00e9sentation orale\u2013 Titre : Outlining Key Regulatory [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[55],"tags":[],"featured-area":[],"news-topic":[73,79],"news-type":[74,75,76,77],"post-year":[],"class_list":["post-3617","post","type-post","status-publish","format-standard","hentry","category-evenements","news-topic-gs010-lumevoq","news-topic-company-and-personnel","news-type-product-candidates","news-type-clinical","news-type-corporate","news-type-conferences"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>4\u00e8me Congr\u00e8s Annuel Gene Therapy for Rare Disorders Europe \u2013 Format virtuel - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/19\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"4\u00e8me Congr\u00e8s Annuel Gene Therapy for Rare Disorders Europe \u2013 Format virtuel - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Gensight Biologics participera \u00e0 la 4\u00e8me \u00e9dition du congr\u00e8s annuel Gene Therapy for Rare Disorders Europe qui se tiendra dans un format virtuel du lundi 26 octobre au mercredi 28 octobre 2020. Magali Taiel, Directeur M\u00e9dical, donnera une pr\u00e9sentation orale et participera \u00e0 un panel de discussion. &nbsp; Pr\u00e9sentation orale\u2013 Titre : Outlining Key Regulatory [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/19\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-19T18:35:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-15T19:57:43+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/19\\\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/19\\\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"4\u00e8me Congr\u00e8s Annuel Gene Therapy for Rare Disorders Europe \u2013 Format virtuel\",\"datePublished\":\"2020-10-19T18:35:19+00:00\",\"dateModified\":\"2026-07-15T19:57:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/19\\\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\\\/\"},\"wordCount\":167,\"articleSection\":[\"Evenements\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/19\\\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/19\\\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\\\/\",\"name\":\"4\u00e8me Congr\u00e8s Annuel Gene Therapy for Rare Disorders Europe \u2013 Format virtuel - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-10-19T18:35:19+00:00\",\"dateModified\":\"2026-07-15T19:57:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/19\\\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/19\\\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/19\\\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"4\u00e8me Congr\u00e8s Annuel Gene Therapy for Rare Disorders Europe \u2013 Format virtuel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"4\u00e8me Congr\u00e8s Annuel Gene Therapy for Rare Disorders Europe \u2013 Format virtuel - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/19\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/","og_locale":"fr_FR","og_type":"article","og_title":"4\u00e8me Congr\u00e8s Annuel Gene Therapy for Rare Disorders Europe \u2013 Format virtuel - GenSight Biologics","og_description":"Gensight Biologics participera \u00e0 la 4\u00e8me \u00e9dition du congr\u00e8s annuel Gene Therapy for Rare Disorders Europe qui se tiendra dans un format virtuel du lundi 26 octobre au mercredi 28 octobre 2020. Magali Taiel, Directeur M\u00e9dical, donnera une pr\u00e9sentation orale et participera \u00e0 un panel de discussion. &nbsp; Pr\u00e9sentation orale\u2013 Titre : Outlining Key Regulatory [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/19\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/","og_site_name":"GenSight Biologics","article_published_time":"2020-10-19T18:35:19+00:00","article_modified_time":"2026-07-15T19:57:43+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/19\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/19\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"4\u00e8me Congr\u00e8s Annuel Gene Therapy for Rare Disorders Europe \u2013 Format virtuel","datePublished":"2020-10-19T18:35:19+00:00","dateModified":"2026-07-15T19:57:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/19\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/"},"wordCount":167,"articleSection":["Evenements"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/19\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/19\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/","name":"4\u00e8me Congr\u00e8s Annuel Gene Therapy for Rare Disorders Europe \u2013 Format virtuel - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2020-10-19T18:35:19+00:00","dateModified":"2026-07-15T19:57:43+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/19\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/19\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/19\/4eme-congres-annuel-gene-therapy-for-rare-disorders-europe-format-virtuel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"4\u00e8me Congr\u00e8s Annuel Gene Therapy for Rare Disorders Europe \u2013 Format virtuel"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3617"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3617\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3617"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3617"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3617"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3617"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}